Lingnan Modern Clinics In Surgery ›› 2021, Vol. 21 ›› Issue (02): 141-145.DOI: 10.3969/j.issn.1009-976X.2021.02.003
• Comment • Previous Articles Next Articles
CHENG Hao，QIU Yu⁃dong
程浩, 仇毓东*
通讯作者:
*仇毓东,Email: yudongqiu510@163.com
作者简介:仇毓东,医学博士,主任医师,教授,博士生导师基金资助:CLC Number:
CHENG Hao, QIU Yu⁃dong. Application of circulating tumor cells in diagnosis and treatment of pancreatic cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(02): 141-145.
程浩, 仇毓东. 循环肿瘤细胞在胰腺癌诊疗中的应用[J]. 岭南现代临床外科, 2021, 21(02): 141-145.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.lingnanwaike.com/EN/10.3969/j.issn.1009-976X.2021.02.003
| [1] Sung H, Ferlay J, Siegel R, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021. doi: 10.3322/caac.21660. [Online ahead of print]. [2] Khomiak A, Brunner M, Kordes M, et al.Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer[J]. Cancers, 2020, 12(11): 3234. [3] Siegel R, Miller K, Fuchs H, Jemal A. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. [4] Egawa S, Toma H, Ohigashi H, et al.Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society[J]. Pancreas, 2012, 41(7): 985-992. [5] Ikemoto J, Serikawa M, Hanada K, et al.Clinical Analysis of Early-Stage Pancreatic Cancer and Proposal for a New Diagnostic Algorithm: A Multicenter Observational Study[J]. Diagnostics, 2021, 11(2): 287. [6] DiPardo B, Winograd P, Court C, Tomlinson J. Pancreatic cancer circulatingtumor cells: applications for personalized oncology[J]. Expert Rev Mol Diagn, 2018, 18(9): 809-820. [7] Allen P, Kuk D, Castillo C, et al.Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma[J]. Ann Surg, 2017, 265(1): 185-191. [8] Pokataev I, Fedyanin M, Polyanskaya E, et al.Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies[J]. ESMO Open, 2020, 5(1): e000578. [9] Seaton M, Hanna A, Boutros C, Hanna N.Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database[J]. Ther Adv Med Oncol, 2019, 11:1758835919842438. [10] Deng A, Wang C, Cohen S, et al.Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis[J]. Eur J Cancer, 2021, 147:17-28. [11] Lee J, Park S, Lee Y, et al.Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA[J]. Mol Oncol, 2019, 13(8): 1623-1650. [12] Martini V, Timme-Bronsert S, Fichtner-Feigl S, et al.Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives[J]. Cancers, 2019, 11(11): 1659. [13] Sagami R, Yamao K, Nakahodo J, et al.Pre-Operative Imaging and Pathological Diagnosis of Localized High-Grade Pancreatic Intra-Epithelial Neoplasia without Invasive Carcinoma[J]. Cancers, 2021, 13(5): 945. [14] Okano K, Suzuki Y.Strategies for early detection of resectable pancreatic cancer[J]. World J Gastroenterol, 2014, 20(32): 11230-11240. [15] Mellby L, Nyberg A, Johansen J, et al.Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer[J]. J Clin Onco, 2018, 36(28): 2887-2894. [16] Kim J, Bamlet W, Oberg A, et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers [J]. Sci Transl Med, 2017, 9(398): eaah5583. [17] Rhim A, Mirek E, Aiello N, et al.EMT and dissemination precede pancreatic tumor formation[J]. Cell, 2012, 148:349-361. [18] Rhim A, Thege F, Santana S, et al.Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions[J]. Gastroenterology, 2014, 146(3): 647-651. [19] Liu H, Sun B, Wang S, et al.Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma[J]. Cell Physiol Biochem, 2017, 42(1): 373-382. [20] Ankeny J, Court C, Hou S, et al.Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer[J]. Br J Cancer, 2016, 114(12): 1367-1375. [21] Sefrioui D, Blanchard F, Toure E, et al.Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours[J]. Br J Cancer, 2017, 117(7): 1017-1025. [22] Wei T, Zhang X, Zhang Q, et al.Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer[J]. Cancer Lett, 2019, 452:237-243. [23] Cheng H, He W, Yang J, et al.Ligand-targeted polymerase chain reaction for the detection of folate receptor-positive circulating tumour cells as a potential diagnostic biomarker for pancreatic cancer[J]. Cell Prolif, 2020, 53(9): e12880. [24] Meng S, Tripathy D, Frenkel E, et al.Circulating tumor cells in patients with breast cancer dormancy[J]. Clin Cancer Res, 2004, 10(24): 8152-8162. [25] Torphy R, Tignanelli C, Kamande J, et al.Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma[J]. PloS One, 2014, 9(2): e89474. [26] Yu K, Ricigliano M, McCarthy B, et al. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma[J]. Cancers, 2018, 10(12): 467. [27] Ren C, Han C, Zhang J, et al.Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy[J]. Cancer Biol Ther, 2011, 12(8): 700-706. [28] Riva F, Dronov O, Khomenko D, et al.Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer[J]. Mol Oncol, 2016, 10(3): 481-493. [29] Tjensvoll K, Nordgård O, Smaaland R.Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications[J]. Int J Cancer, 2014, 134(1): 1-8. [30] Court C, Ankeny J, Sho S, et al.Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer[J]. Ann Surg Oncol, 2018, 25(4): 1000-1008. [31] Song B, Kwon W, Kim H, et al.Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker[J]. Front Oncol, 2020, 10:616440. [32] Wang Y, Yu X, Hartmann D, Zhou J.Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: a systematic review and meta-analysis[J]. HPB, 2020, 22(5): 660-669. [33] Umer M, Vaidyanathan R, Nguyen N, Shiddiky M.Circulating tumor microemboli: Progress in molecular understanding and enrichment technologies[J]. Biotechnol Adv, 2018, 36(4): 1367-1389. [34] Chang M, Chang Y, Chen J, et al.Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma[J]. Clin Chem, 2016, 62(3): 505-513. [35] Wu G, Zhu R, Li Y, et al.Prognostic significance of circulating tumor microemboli in patients with pancreatic ductal adenocarcinoma[J]. Oncol Lett, 2018, 15(5): 7376-7382. [36] Micalizzi D, Haber D, Maheswaran S.Cancer metastasis through the prism of epithelial-to-mesenchymal transition in circulating tumor cells[J]. Mol Oncol, 2017, 11(7): 770-780. [37] Lowes L, Allan A.Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition[J]. Adv Clin Chem, 2018, 83:121-181. [38] Gemenetzis G, Groot V, Yu J, et al.Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study[J]. Ann Surg, 2018, 268(3): 408-420. [39] Poruk K, Valero V, Saunders, et al. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma[J]. Ann Surg, 2016, 264(6): 1073-1081. [40] Amantini C, Morelli M, Nabissi M, et al.Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival[J]. Front Oncol, 2019, 9:874. [41] Sergeant G, van Eijsden R, Roskams T, et al. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery[J]. BMC Cancer, 2012, 12:527. [42] Poruk K, Blackford A, Weiss M, et al.Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma[J]. Clin Cancer Res, 2017, 23(11): 2681-2690. [43] Hussain S.Pancreatic Cancer: Current Progress and Future Challenges[J]. Int J Biol Sci, 2016, 12(3): 270-272. [44] Tien Y, Kuo H, Ho B, et al.A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts Liver Metastases[J]. Medicine, 2016, 95(16): e3407. [45] White M, Lee A, Vicente D, et al.Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma[J]. Ann Surg Oncol, 2021. doi: 10.1245/s10434-020-09518-y.[Online ahead of print] [46] Tao L, Su L, Yuan C, et al.Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer[J]. Cancer Manag Res, 2019, 11:7405-7425. [47] Catenacci D, Chapman C, Xu P, et al. Acquisition of Portal Venous Circulating Tumor Cells FromPatients With Pancreaticobiliary Cancers by EndoscopicUltrasound [J]. Gastroenterology, 2015, 149(7): 1794-1803. e4. [48] Chapman C, Ayoub F, Swei E, et al.Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers[J]. Pancreatology, 2020, 20(8): 1747-1754. [49] Arnoletti J, Zhu X, Almodovar A, et al.Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation[J]. Pancreas, 2017, 46(1): 116-123. [50] Arnoletti J, Fanaian N, Reza J, et al.Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation[J]. Cancer Biolo Ther, 2018, 19(10): 887-897. |
| [1] | LONG Yin, SONG Xing-dong, ZHANG Lei. Several focus issues of conversion therapies for intermediate-advanced hepatocellular carcinoma [J]. Lingnan Modern Clinics In Surgery, 2022, 22(02): 115-119. |
| [2] | DENG Jing, CHEN Huan-wei. Comparative study on the safety and efficacy of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy [J]. Lingnan Modern Clinics In Surgery, 2022, 22(02): 120-125. |
| [3] | HE Chong, ZHOU Shu-rui, LI Ya-qing, CHEN Shao-jie, LIAN Guo-da, CHEN Shang-xiang, HUANG Kai-hong. Screening of ferroptosis-related genes and construction of prognostic prediction model in pancreatic cancer [J]. Lingnan Modern Clinics In Surgery, 2022, 22(01): 14-23. |
| [4] | LIN Xing-yi, TIAN Zhen-feng, PAN Le-le, SU Ming-xin, CHEN Yin-ting. Metabolic pathways and key gene analysis of circulating tumor cells in pancreatic cancer based on GEO database [J]. Lingnan Modern Clinics In Surgery, 2022, 22(01): 34-41. |
| [5] | LOU Wen-hui. Whole disease journey management in the diagnosis and treatment of pancreatic cancer [J]. Lingnan Modern Clinics In Surgery, 2021, 21(01): 1-5. |
| [6] | HAN Shi-ji, LIAN Guo-da, CHEN Shao-jie, HUANG Kai-hong, LI Jia-jia. Construction and functional verification of immortalized human pancreatic stellate cells [J]. Lingnan Modern Clinics In Surgery, 2021, 21(01): 36-43. |
| [7] | YUAN Guan-ping, JIANG Zhi-min, MA Dong, PAN Zi-chun, DING Ying, XIE De-rong. FOLFIRINOX regimen versus AG regimen as first-line therapy in advanced pancreatic cancer： A multicenter observational study [J]. Lingnan Modern Clinics In Surgery, 2021, 21(01): 53-58. |
| [8] | HUANG Xian-xian, LI Yuan-hua, HUANG Feng-ting, ZHANG Shi-neng, ZHUANG Yan-yan.. Effect on biological function after XPO1 knockout in pancreatic cancer cell line via CRISPR/Cas9 [J]. Lingnan Modern Clinics in Surgery, 2020, 20(03): 280-284. |
| [9] | PENG Ning-fu, ZHONG Jian-hong, ZHU Shao-liang, LIAO Ying-yang, LI Le-qun. Research status of commonality between cancerous and precancerous lesions of the biliary tract and the pancreas [J]. Lingnan Modern Clinics in Surgery, 2020, 20(02): 261-266. |
| [10] | LI Xuan-na, CHEN Shang-xiang, LIAN Guo-da, CHEN Shao-jie, HUANG Kai-hong. Analysis of clinicopathological features of 240 cases of pancreatic cancer with liver metastasis and prognostic risk factors [J]. Lingnan Modern Clinics in Surgery, 2020, 20(02): 151-154. |
| [11] | LI Zitao， MIAO Huilai. Advances in the diagnosis and treatment of pancreatic cystic tumors by endoscopic ultrasonography [J]. Lingnan Modern Clinics in Surgery, 2019, 19(01): 106-109. |
| [12] | REN Xiaofan1， LI zhihua1. Expression and clinical significance of exosomal long non?coding RNA CCAT1 in pancreatic cancer [J]. Lingnan Modern Clinics in Surgery, 2019, 19(01): 23-27. |
| [13] | ZHANG Guangtao1， LIANG Yue2， LI Minghua3. Construction and verification of plasmid mediated LAPTM4B over expressing pancreatic cancer cell line PANC?1 [J]. Lingnan Modern Clinics in Surgery, 2019, 19(01): 44-47. |
| [14] | WEI Lusheng, LU Yuanting, YE Huilin, ZHOU Quanbo, CHEN Rufu. Expression and clinical significance of SATB-1 and α-SMA in pancreatic cancer [J]. Lingnan Modern Clinics in Surgery, 2018, 18(02): 195-200. |
| [15] | WU Gang，LI Li. Diagnosis and treatment of 5 cases of insulinoma [J]. Lingnan Modern Clinics in Surgery, 2017, 17(06): 699-700. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
